Table 1 Demographics for individuals with ME/CFS taking aripiprazole (Abilify)
Demographics | Responders | Non-responders | Total |
|---|---|---|---|
Individuals with ME/CFS, n (%) | 75 (74.3%) | 26 (25.8%) | 101 (100%) |
Mean age, years (range) | 48.9 (18–76) | 52.2 (28–84) | 49.7 (18–84) |
Duration of illness, years (range) | 12.6 (2–54) | 15.8 (1–44) | 13.4 (1–54) |
Female, n (%) | 52 (69.4%) | 16 (61.5%) | 68 (67%) |
Male, n (%) | 23 (30.6%) | 10 (38.5%) | 33 (33%) |
Aripiprazole dose, mg (range) | 1.2 (0.25–2.0) | 0.7 (0–2.0) | 1.1 (0–2.0) |
Duration of treatment, average months (range) | 8.0 (0–17) | 7.1 (0–13) | 7.8 (0–17) |
Concurrent antidepressant use | 46/75 (61.3%)* | 11/26 (42.3%)* | 57/101 (56.4%) |